FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年12月2日 FF305 FF305 | 1). | 購回股份（擬註銷但尚未註銷） | | 232,000 | 0.0983 % | HKD | 29.4622 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年10月20日 | | | | | | 2). | 購回股份（擬註銷但尚未註銷） | | 149,600 | 0.0634 % | HKD | 29.7048 | | | 變動日期 | 2025年10月21日 | | | | | | 3). | 購回股份（擬註銷但尚未註銷） | | 91,300 | 0.0387 % | HKD | 30.1128 | | | 變動日期 | 2025年10月22日 | | | | | | 4). | 購回股份（擬註銷但尚未註銷） | | 198,600 | 0.0841 % | HKD | 29.5236 ...

| 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) 02273 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | 於下列日期開始時的結存(註1) 2025年11月28日 | | 229,923,692 | | 1,645,200 | | | | 231,568,892 | | 1). 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | | 216,460 | 0.0941 % | | HKD | 2 ...

Core Viewpoint - The company, Guoshengtang (02273), announced the allocation of new shares to eligible participants under a previously restricted share award plan, indicating a commitment to employee incentives and retention strategies [1] Group 1 - On December 1, 2025, the company will distribute 216,500 new shares to 121 eligible participants as part of the share award plan [1] - Additionally, on the same date, the company will allocate 2,585,700 new shares to 95 eligible participants, reflecting a significant distribution of shares under the incentive program [1]

Group 1 - The company, Gushengtang (02273), announced the allocation of 216,500 new shares to 121 qualified participants under a previously restricted share award plan on December 1, 2025 [1] - Additionally, the company will allocate 2,585,700 new shares to 95 qualified participants on the same date under the same restricted share award plan [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年12月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) 02273 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股 ...

Investment Rating - The report maintains a positive outlook on the innovative drug sector, indicating a rebound and potential for further growth in the upcoming months [3][6]. Core Insights - The innovative drug sector is expected to see a rebound after previous adjustments, with significant catalysts anticipated in December and January. The results of the national medical insurance negotiations will be released in early December, which may impact the inclusion of domestic innovative drugs in the insurance catalog [3][14]. - The upcoming American Society of Hematology (ASH) conference from December 6-9 is highlighted as a key event, with multiple differentiated hematology products expected to present new data [3][4][42]. - The CXO sector shows a continuous upward trend, supported by the rapid growth of new orders and backlog, ensuring performance release in the next 1-2 years [4][53]. Summary by Sections Innovative Drugs - The report emphasizes the importance of focusing on dual/multi-target drugs for various cancers and chronic diseases, as well as opportunities in ADCs and small nucleic acid therapies [6][15]. - The report notes that the innovative drug financing data is showing marginal improvement, indicating a potential recovery in the sector [6][15]. Biologics - The report mentions positive preliminary results from the Phase II clinical trial of amycretin for Type 2 diabetes, suggesting continued monitoring of its clinical progress [4][46]. Medical Devices - The report highlights the emergence of innovative domestic medical devices, with expectations for profit margins to stabilize and improve as new products are approved [5]. Traditional Chinese Medicine & Pharmacies - The report suggests monitoring companies with strong brand power and good inventory management, such as China Resources Sanjiu and Jichuan Pharmaceutical, due to rising flu incidence [5]. Medical Services and Consumer Healthcare - The report discusses a collaboration between a traditional Chinese medicine group and a local health bureau to enhance the capabilities of grassroots medical services through technology [5]. Key Investment Targets - The report identifies key companies to watch, including Innovent Biologics, Kintor Pharmaceutical, and others in the innovative drug and medical device sectors [7].

Summary of Key Points Core Viewpoint - The company, Guosheng Tang, has been actively repurchasing its shares, indicating a strategy to enhance shareholder value and confidence in its stock performance [2][3]. Share Buyback Details - On November 28, Guosheng Tang repurchased 287,600 shares at a price range of HKD 29.620 to HKD 30.000, totaling HKD 8.5854 million [2]. - The stock closed at HKD 29.920 on the same day, reflecting a slight increase of 0.07% with a total trading volume of HKD 32.6032 million [2]. - Since November 25, the company has conducted buybacks for four consecutive days, acquiring a total of 1,145,200 shares for a cumulative amount of HKD 34.1144 million, during which the stock price increased by 1.22% [2]. Year-to-Date Buyback Activity - Year-to-date, Guosheng Tang has executed 68 buyback transactions, acquiring a total of 12,697,800 shares for a total expenditure of HKD 387 million [3].

Core Viewpoint - The company, Guoshengtang (02273), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will spend HKD 8.5854 million to repurchase 287,600 shares [1] - The buyback price per share ranges from HKD 29.62 to HKD 30 [1]

Core Viewpoint - The company, Guoshengtang (02273.HK), announced a share buyback on November 28, 2023, spending HKD 8.585 million to repurchase 288,000 shares [1] Summary by Category Company Actions - Guoshengtang executed a buyback of 288,000 shares at a total cost of HKD 8.585 million on November 28, 2023 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年11月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...